FMP
Elevation Oncology, Inc.
ELEV
NASDAQ
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
0.58 USD
-0.0457 (-7.88%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Joseph J. Ferra Jr.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
CIK
0001783032
ISIN
US28623U1016
CUSIP
28623U101
Address
888 Seventh Avenue
Phone
716 371 1125
Country
US
Employee
29
IPO Date
Jun 25, 2021
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ELEV Financial Summary
CIK
0001783032
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
28623U101
ISIN
US28623U1016
Country
US
Price
0.58
Beta
1.25
Volume Avg.
763.65k
Market Cap
34.29M
Shares
-
52-Week
0.44-5.83
DCF
0.56
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.72
P/B
-
Website
https://elevationoncology.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ELEV News
It looks like there's no news available.
